Biotechnology 28 May 2026 - 2 June 2026

Aura Biosciences Stock Falls After Eye-Cancer Trial News
····

Aura Biosciences Stock Falls After Eye-Cancer Trial News

Aura Biosciences shares dropped roughly 4.2% to $6.89 late Tuesday, lagging a soft biotech sector. This came after Aura said on Monday that it hit a clinical-trial milestone. The SPDR S&P Biotech ETF slid about 4.2%. The iShares Nasdaq Biotechnology ETF lost around 2.9%. Aura said Monday it finished enrolling 108 patients in CoMpass, its Phase 3 study of bel-sar for early choroidal melanoma. Phase 3 trials are key late-stage tests before a drug approval. The first main results, or “topline” data, are due in the second half of 2027.
June 2, 2026
VivoSim Stock Sits Near 52-Week Low, Biotech Faces Pre-Market Cash Crunch
····

VivoSim Stock Sits Near 52-Week Low, Biotech Faces Pre-Market Cash Crunch

VivoSim Labs slipped in early pre-market trade Tuesday, last quoted at $1.29, off around 0.8%. The drug-testing microcap is trading just above its 52-week low of $1.22, with a market cap near $3.36 million. That small move stands out since biotech was weak before the bell. The SPDR S&P Biotech ETF was off 2.2% in the latest trading. The iShares Nasdaq Biotechnology ETF lost 1.6%. That drop adds pressure, especially on smaller stocks where trading is light.
June 2, 2026
Genprex trades under $1 as ASCO results land
····

Genprex trades under $1 as ASCO results land

Genprex Inc. stock stayed close to Monday’s low before the next U.S. trading session, keeping the Nasdaq Capital Market gene therapy name below $1. Investors were watching new lung-cancer biomarker data, while funding remained a concern. June 2 isn’t on the Nasdaq's 2026 market holiday schedule. GNPX was last quoted at $0.7501, about 4% lower than its previous close. That puts the company’s market cap near $7.9 million. Monday’s session saw the stock drop 3.77%, opening at $0.78, hitting a high of $0.79, and bottoming at $0.72 before closing at $0.75. About 401,000 shares changed hands.
June 2, 2026
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data
····

Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data

Aclaris Therapeutics dropped 12.5 cents to $4.43 late Monday, underperforming broad biotech indexes after little recent news from the drugmaker. The SPDR S&P Biotech ETF lost 1.9%. The iShares Nasdaq Biotechnology ETF slid 1.4%. An ETF is a basket of securities trading like a single stock. Aclaris’ next shot with investors is coming up. The Wayne, Pennsylvania company said CEO Dr. Neal Walker and other executives will take part in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday at 2 p.m. ET. Its investor-relations site hasn’t posted anything newer than the May 28 release.
June 1, 2026
Cellectis Shares Dip Ahead of June Data Investors Wait For
····

Cellectis Shares Dip Ahead of June Data Investors Wait For

Cellectis S.A. ADRs slipped Monday, with the U.S.-listed gene-editing biotech trading near session lows. Shares last quoted at $3.44, down 8 cents, or 2.3%. Cellectis opened at $3.55, hit a high of $3.69, and traded only 37,375 shares in light action. Cellectis shares dropped in a slumping biotech sector, with no new disclosure from the company. The SPDR S&P Biotech ETF finished down roughly 1.7%. The iShares Nasdaq Biotechnology ETF slid 1.4%. Cellectis’ most recent update on its press page was a May 20 announcement about its June 25 annual meeting.
June 1, 2026
Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision
····

Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision

Inovio Pharmaceuticals shares moved lower Monday after H.C. Wainwright trimmed its price target for the DNA-medicine firm. The call brought attention back to dilution and an upcoming U.S. regulatory ruling expected this year. INO was recently at $1.275, off 2.7%. More than 1 million shares traded hands. H.C. Wainwright cut its price target on the stock to $2.50 from $3.00 and kept a Neutral rating, market reports said. StreetInsider pointed to Raghuram Selvaraju as the analyst behind the move. Benzinga’s analyst-ratings page showed the firm made the target cut on June 1 and held its Neutral stance.
June 1, 2026
REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore
·····

REGENXBIO Stock Barely Moves — The Gene-Therapy Test Wall Street Can’t Ignore

REGENXBIO Inc shares were little changed in Monday morning trading, down about 0.6% at $6.97 at 10:47 a.m. EDT, as the small-cap gene-therapy developer moved without a new company-specific catalyst. The stock traded between $6.85 and $7.15, with a market value of about $365 million. Regular trading was under way on Nasdaq, whose U.S. market runs from 9:30 a.m. to 4 p.m. Eastern Time on standard weekdays. June 1 was not listed among Nasdaq’s 2026 market holidays.
June 1, 2026
Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching
····

Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching

Vistagen Therapeutics shares were little changed before the regular Nasdaq open on Monday, quoted around $0.63, as investors looked past a quiet weekend and toward a trial-data window that could set the next move in the small biotech stock. U.S. equity markets were on a normal schedule; Nasdaq’s 2026 calendar lists the next June closure as Juneteenth on June 19. The timing matters. Vistagen, valued at about $26.6 million, is heading into June with its lead anxiety drug still carrying most of the equity story, while the SPDR S&P Biotech ETF, a broad gauge of biotech risk appetite, was modestly firmer before the open.
June 1, 2026
Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await
····

Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await

Cabaletta Bio shares gained in light premarket action Monday, bouncing after drifting out of focus for some traders. The autoimmune cell-therapy firm is set to appear at a healthcare conference in two days, with key clinical data due out in London later this week. Shares ended Friday at $3.78. Pre-market quotes showed the stock at $3.92, a 3.7% gain. Only a few thousand shares traded before the bell, so the premarket jump could fade when the Nasdaq opens.
June 1, 2026
TScan Therapeutics hangs around $1.08; eyes on next week
····

TScan Therapeutics hangs around $1.08; eyes on next week

TScan Therapeutics heads into June as investors wait for the next clinical update. Shares ended Friday at $1.08, with trading volume light ahead of the weekend and U.S. markets closed. The stock moved between $1.04 and $1.13 through the shortened week, historical data from the company showed. TScan is flagging early data for Cohort C in its ALLOHA Phase 1 blood-cancer trial for the second quarter and also says it wants to start a Phase 3 trial of TSC-101 in that same quarter. A Phase 3 trial is late-stage and usually backs a regulatory filing.
May 31, 2026
Novavax Shares Gain 19% in Short Week
····

Novavax Shares Gain 19% in Short Week

Novavax Inc. heads into the week after a jump over four sessions. U.S. markets were closed over the weekend. The stock finished Friday at $10.97, up 6.3% that day, gaining around 19% since May 22. Nasdaq stayed shut Monday for Memorial Day, so trading will run on a shorter schedule. This matters now because the U.S. Food and Drug Administration told approved COVID-19 vaccine makers Friday that shots for the 2026-2027 season should use the JN.1-lineage XFG variant in a monovalent vaccine — a single-strain shot.
May 31, 2026
Lyell Quiet as Bigger CAR-T Question Lingers for Investors
····

Lyell Quiet as Bigger CAR-T Question Lingers for Investors

Lyell Immunopharma stock posted a late rebound to close out the short week, gaining almost 3% to finish at $17.33 on Friday. Shares moved in a $16.30 to $17.475 range, according to Investing.com. The cancer cell-therapy name lagged the broader U.S. market. Lyell is still trading as a clinical-readout story, not on earnings. Its value depends on whether its main CAR T-cell drug, ronde-cel, can deliver enough on safety and efficacy to compete with approved therapies for large B-cell lymphoma.
May 31, 2026
Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus
····

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech shares are on a four-day losing streak on Nasdaq as the new week begins. Investors are watching for a Sunday evening cancer conference event that could be key for the stock’s direction. Legend Biotech shares ended Friday at $27.16, losing 3.89% on the session. The stock is now trading about 7.5% lower than the previous Friday’s close of $29.37. U.S. markets saw a shortened week due to the Memorial Day holiday. Nasdaq is closed Sundays and trades Monday to Friday, 9:30 a.m. to 4 p.m. ET.
May 31, 2026
IDEAYA Holds Steady Heading Into ASCO—Traders Watch for Next Mover on IDYA
····

IDEAYA Holds Steady Heading Into ASCO—Traders Watch for Next Mover on IDYA

IDEAYA Biosciences edged higher in a holiday-shortened week, finishing Friday at $29.47, up 0.4%. Shares added about 1.3% from the previous week’s close. Investors shrugged off an employee stock-option grant and focused on cancer-drug results expected at ASCO this week. U.S. stock trading paused Monday for Memorial Day, leaving the week with only four sessions. Markets are closed again for the weekend. According to Nasdaq’s 2026 holiday calendar, May 25 will also be a full closure for Memorial Day.
May 31, 2026
RKTO’s Friday Drop Came After Big Gains for Hoth Therapeutics Traders
····

RKTO’s Friday Drop Came After Big Gains for Hoth Therapeutics Traders

Rocket One Inc., which used to be called Hoth Therapeutics, dropped 14.1% to close at $1.46 on Friday. Shares slipped further to $1.384 after the bell, according to StockAnalysis. The stock pulled back after its rapid jump tied to a move from biotech into AI and space. That’s important now since the HOTH ticker isn’t trading anymore. A filing showed the legal name became Rocket One Inc. as of May 26. Nasdaq switched the ticker to RKTO on May 28. Shareholder rights and the CUSIP number stayed the same.
May 31, 2026
Enveric Biosciences Stock Slips as Cash Questions Hang Over ENVB
····

Enveric Biosciences Stock Slips as Cash Questions Hang Over ENVB

Enveric Biosciences shares fell Friday, with the stock hanging near recent lows. The small-cap biotech had little news, and investors are watching for progress with its main drug candidate before human trials. The stock closed at $2.30 on Nasdaq, slipping 0.86%. Shares traded in a range of $2.20 to $2.41. Market cap stood near $8.47 million. The 52-week span is $1.71 to $17.64, showing the wide swings in the stock.
May 29, 2026
Orchestra BioMed Shares Trade Lower Ahead of Trial Milestone
····

Orchestra BioMed Shares Trade Lower Ahead of Trial Milestone

Orchestra BioMed Holdings shares fell in Friday afternoon trade. Investors seemed to look ahead to upcoming milestones for its Medtronic-partnered hypertension therapy, while the news flow stayed quiet. The stock traded lower, falling 0.8% to $3.95 as roughly 116,000 shares changed hands. The move trailed the broader biotech sector, where the SPDR S&P Biotech ETF added 0.4%, but the iShares Nasdaq Biotechnology ETF slipped 0.2%.
May 29, 2026
Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June
····

Relay Therapeutics Shares Reclaim Offer Price as Traders Eye June

Relay Therapeutics traded up on Thursday, staying above last week’s public offer price. Some investors moved past dilution concerns and turned attention to two June investor events, with management expected to field questions about lead asset zovegalisib. Shares were at $14.50 as of 11:46 a.m. EDT, up roughly 0.5%. The SPDR S&P Biotech ETF was also up 0.6%, and the iShares Nasdaq Biotechnology ETF added 0.9%. Relay is moving fast. The company said Wednesday that management will appear at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 8. Those showings come less than two weeks after Relay ran a stock sale and dropped new clinical data in its rare-disease program.
May 28, 2026
····

Xerox pops after 15 million-share filing seen as turnaround signal

Xerox Holdings shares traded higher Thursday after a new SEC filing disclosed the updated share count, as the office-technology company works on its turnaround plan. Xerox inched up 8 cents to $3.18 on Nasdaq. Volume was about 1.6 million shares, giving the company a market value of $416 million. The stock moved between $3.05 and $3.23 during the session. The Nasdaq Composite and S&P 500 both closed flat.
May 28, 2026
Jade Biosciences Gets Two Catalysts, but Focus Is on 2027
····

Jade Biosciences Gets Two Catalysts, but Focus Is on 2027

Jade Biosciences is set to open Thursday in the U.S. after announcing it started dosing patients in two clinical trials. The company said it began a Phase 2 study in kidney disease and a first-in-human study in rheumatoid arthritis. Shares last changed hands at $21.50, off 21 cents from the previous close, in premarket activity. That’s important as Jade shifts from early promise to actual patient data. A Phase 2 study gives an early look at whether a drug helps patients, while Phase 1 is just the initial test in people, mainly covering safety, drug exposure, and first biological effects.
May 28, 2026
1 2 3 … 5